Janux Therapeutics, Inc. (JANX) Shareholder Equity
- 2026-06-30: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $61.00K; Additional Paid in Capital, Common StockUSD $1.33B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-2.31M.
- 2026-03-31: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $60.00K; Additional Paid in Capital, Common StockUSD $1.32B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $576.00K.
- 2025-12-31: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $60.00K; Additional Paid in Capital, Common StockUSD $1.30B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $4.32M.
- 2025-09-30: Preferred Stock, Value, IssuedUSD (m); Common Stock, Value, IssuedUSD $60.00K; Additional Paid in Capital, Common StockUSD $1.29B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $4.56M.
Janux Therapeutics, Inc. Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Preferred Stock, Value, Issued USD | Common Stock, Value, Issued USD | Additional Paid in Capital, Common Stock USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs USD | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $0.00 | $61.00K | $1.33B | $-2.31M | $-397.71M | $927.98M | (m) | 3 month · $9.06M 6 month · $18.33M |
| 2026-03-31 | $0.00 | $60.00K | $1.32B | $576.00K | $-375.74M | $941.53M | (m) | 3 month · $9.27M |
| 2025-12-31 | $0.00 | $60.00K | $1.30B | $4.32M | $-351.38M | $956.82M | (m) | 12 month · $40.22M |
| 2025-09-30 | (m) | $60.00K | $1.29B | $4.56M | $-319.44M | $976.55M | (m) | 3 month · $9.04M 9 month · $30.71M |
| 2025-06-30 | (m) | $59.00K | $1.28B | $3.75M | $-295.12M | $990.52M | (m) | 3 month · $10.96M 6 month · $21.66M |
| 2025-03-31 | (m) | $59.00K | $1.27B | $3.76M | $-261.26M | $1.01B | (m) | 3 month · $10.70M |
| 2024-12-31 | (m) | $59.00K | $1.26B | $2.16M | $-237.76M | $1.02B | (m) | 12 month · $33.02M |
| 2024-09-30 | (m) | $52.00K | $865.76M | $7.83M | $-217.54M | $656.10M | (m) | 3 month · $15.39M 9 month · $26.77M |
| 2024-06-30 | (m) | $52.00K | $848.72M | $-1.62M | $-189.48M | $657.68M | 3 month · $17.00K | 3 month · $5.76M 6 month · $11.38M |
| 2024-03-31 | (m) | $51.00K | $839.76M | $-524.00K | $-183.52M | $655.76M | (m) | 3 month · $5.62M |
| 2023-12-31 | (m) | $46.00K | $512.40M | $665.00K | $-168.76M | $344.35M | (m) | 12 month · $20.00M |
| 2023-09-30 | (m) | $46.00K | $507.08M | $-1.18M | $-157.00M | $348.95M | (m) | 3 month · $4.55M 9 month · $15.52M |
| 2023-06-30 | (m) | $42.00K | $445.92M | $-1.06M | $-145.44M | $299.47M | (m) | 3 month · $5.50M 6 month · $10.97M |
| 2023-03-31 | (m) | $42.00K | $439.89M | $-739.00K | $-127.93M | $311.26M | (m) | 3 month · $5.47M |
| 2022-12-31 | (m) | $42.00K | $432.70M | $-1.53M | $-110.47M | $320.74M | (m) | 12 month · $17.20M |
| 2022-09-30 | (m) | $42.00K | $428.15M | $-2.28M | $-94.41M | $331.51M | (m) | 3 month · $4.60M 9 month · $13.00M |
| 2022-06-30 | (m) | $42.00K | $423.39M | $-1.91M | $-77.71M | $343.81M | (m) | 3 month · $4.44M 6 month · $8.40M |
| 2022-03-31 | (m) | $41.00K | $418.43M | $-1.57M | $-60.82M | $356.08M | (m) | 3 month · $3.96M |
| 2021-12-31 | (m) | $41.00K | $413.97M | $-270.00K | $-47.41M | $366.33M | (m) | 12 month · $6.91M |
| 2021-09-30 | (m) | $41.00K | $410.68M | $24.00K | $-33.99M | $376.75M | (m) | 3 month · $2.57M 9 month · $3.97M |
| 2021-06-30 | (m) | $41.00K | $407.97M | $17.00K | $-23.23M | $384.80M | (m) | 3 month · $1.28M 6 month · $1.40M |
| 2021-03-31 | (m) | (m) | (m) | (m) | (m) | $-16.77M | (m) | 3 month · $123.00K |
| 2020-12-31 | (m) | $1.00K | $100.00K | $0.00 | $-14.74M | $-14.64M | (m) | 12 month · $72.00K |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | $-13.04M | (m) | 3 month · $28.00K 9 month · $32.00K |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | $-11.81M | (m) | 3 month · $2.00K 6 month · $4.00K |
| 2020-03-31 | (m) | (m) | (m) | (m) | (m) | $-9.35M | (m) | (m) |
| 2019-12-31 | (m) | (m) | (m) | (m) | (m) | $-7.94M | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |